RE:RE:ONCY’s Phase 1b/2 mPC results compared over 2019 to 2023The PanCan US$5 million sponsored pelareorep + mFOLFIRINOX + atezolizumab clinical trial would follow on the coat-tails of the pelareorep + atezolizumab + gemcitibine + nab-paclitaxel filing, IMO.